Skip to main content

Table 1 Clinical outcomes in children with juvenile dermatomyositis in Africa among survey respondents (n = 20)

From: Exploring the clinical profiles and management of juvenile dermatomyositis in Africa: a survey of African rheumatology care providers

Country (Number of Respondents)

Total Patients (n = 216)*

Clinically Inactive Disease†

Remission‡

Calcinosis

Interstitial Lung Disease

Deaths

Northern Africa (12; 60%)

      

 Egypt (6]

68*

28

13

36

5

2

 Libya [3]

55*

18+

39+

12

5+

3

 Morocco [1]

19

6 (31.6%)

4 (21.1%)

7 (36.8%)

6 (31.6%)

0 (0%)

 Tunisia [2]

3*

6

6

0

4

0+

Eastern Africa (3; 15%)

      

 Kenya [2]

42

15 (35.7%)

12 (28.6%)

13 (31.0%)

8 (19.0%)

6 (14.3%)

 Zambia [1]

7

5 (71.4%)

0 (0%)

3 (42.9%)

1 (14.3%)

2 (28.6%)

Central Africa (3; 15%)

      

 Cameroon [2]**

11

6 (54.5%)

5 (45.5%)

3 (27.3%)

2 (18.2%)

0 (0%)

 Democratic Republic of the Congo [1]**

3

3 (100%)

1 (33.3%)

3 (100%)

0 (0%)

+

Western Africa (1; 5%)

      

 Nigeria [1]

4

2 (50.0%)

1 (25.0%)

0 (0%)

1 (25.0%)

0 (0%)

Southern Africa (1; 5%)

      

 South Africa [1]

4

1 (25.0%)

1 (25.0%)

2 (50.0%)

0 (0%)

0 (0%)

  1. Number of patients reported as n; (%) also reported when total patients known
  2. *At least 1 respondent unsure of total number of patients, therefore number provided is an underestimation and percentages were unable to be calculated; Egypt = 3 of 6 respondents unsure about prior patients, Libya = 1 of 3 respondents unsure about total current and total prior patients, Tunisia = 2 of 2 respondents unsure about total current patients and 1 of 2 unsure about prior patients.
  3. † Defined as lack of evidence of myositis disease activity as assessed by global and extra-muscular assessments, stable muscle strength and function, and normal muscle enzyme levels, as per the International Myositis Assessment & Clinical Studies (IMACS) criteria for lack of evidence of active myositis
  4. ‡ Defined according to the IMACS 2005 definition: clinically inactive disease while not receiving any drug therapy for a 6-month continuous period
  5. **Respondents answered questions only about current, not prior, patients (Cameroon = 1 respondent, Democratic Republic of Congo = 1 respondent)
  6. + Response missing from 1 respondent